Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
entities : Teva pharmaceutical industries ltd crawled date : 2022 - 04 - 07 save search
Press Release: Dupixent® (dupilumab) approved by European Commission for children aged 6 to 11 years with severe asthma with type 2 inflammation
Published: 2022-04-07 (Crawled : 08:00) - biospace.com/
SNYNF | News | $94.25 480
|
Health Technology
|
| O: 4.21%
H: 0.0%
C: -0.61%
SNY | News | $46.82 -1.82% 510K
|
Health Technology
|
| O: 1.74%
H: 0.0%
C: 0.0%
REGN | News | $911.73 0.49% 97K
|
Health Technology
|
| O: -0.3%
H: 2.79%
C: 2.2%
dupixent children
Dupixent® (dupilumab) Approved by European Commission for Children Aged 6 to 11 Years with Severe Asthma with Type 2 Inflammation
Published: 2022-04-07 (Crawled : 06:00) - prnewswire.com
SNYNF | News | $94.25 480
|
Health Technology
|
| O: 4.21%
H: 0.0%
C: -0.61%
SNY | News | $46.82 -1.82% 510K
|
Health Technology
|
| O: 1.74%
H: 0.0%
C: 0.0%
REGN | News | $911.73 0.49% 97K
|
Health Technology
|
| O: -0.3%
H: 2.79%
C: 2.2%
dupixent children
Gainers vs Losers
| 58% | 42% |
Top 10 Gainers
CSSE 4 | $0.3686 142.02% 76M
|
Consumer Services
CZOO | $11.685 134.17% 7.6M
|
BOF | $1.93 64.96% 55M
|
AMST | $3.14 57.0% 59M
|
Technology Services
LICN | $0.7885 40.8% 11M
|
TROO | $1.51 38.53% 5.6M
|
Manufacturing
MULN | News | $3.7 35.53% 6.4M
|
Information
WHLM | $6.61 30.12% 400K
|
Commercial Services
RILY | $27.91 28.5% 8.9M
|
Finance
RBBN 4 | $3.25 26.46% 1.5M
|
Electronic Technology
Your saved searches
Save your searches and get alerts when important news are released.